Transcept Pharmaceuticals (TSPT) jumps in the post-session after the company announces its will...
Transcept Pharmaceuticals (TSPT) jumps in the post-session after the company announces its will resubmit its New Drug Application to the FDA seeking its approval of Intermezzo. Earlier today the FDA had notified the company that it generally agreed with its new proposals following the drug's rejection in July. Shares +13.7% AH.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs